1)Raina P, et al:Effectiveness of cholinesterase inhibitors and memantine for treating dementia;Evidence review for a clinical practice guideline. Ann Intern Med 148:379-397, 2008
2)Hansen RA, et al:Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease;A systematic review and meta-analysis. Clin Interv Aging 3:211-225, 2008
3)Wang L, et al:Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. Arch Neurol 67:99-106, 2010
4)Kröger E, et al:Adverse drug reactions reported with cholinesterase inhibitors;An analysis of 16 years of individual case safety reports from Vigibase. Annals of Pharmacotherapy 49:1197-1206, 2015
5)Birks J, Harvey RJ:Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006:CD001190, 2006
6)Reisberg B, et al:Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341, 2003
7)Doody RS, et al:Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement 3:7-17, 2007
8)Homma A, et al:Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 11:299-313, 2000
9)Meguro K, Yamaguchi S:Decreased behavioral abnormalities after treatment with combined donepezil and Yokukansankachimpihange in Alzheimer Disease;An observational study. The Osaki-Tajiri Project. Neurol Ther 7:333-340, 2018
10)日本神経学会(監),「認知症疾患診療ガイドライン」作成委員会(編):認知症疾患治療ガイドライン2017,p 227,医学書院,2017
11)Sclan SG, Reisberg B:Functional assessment staging(FAST)in Alzheimer's disease;Reliability, validity, and ordinality. Int Psychogeriatr 4 Suppl 1:55-69, 1992
12)中村 祐:アルツハイマー病治療薬はいつまで投与すべきか? 精神誌111:43-48, 2009